Solvotrin sets its sights on EIIS funding boost

22nd November, 2015
Iron for the 21st Century – Solvotrin’s new iron product has been clinically proven to be twice as good the market leader and gentle enough to be taken on an empty stomach

Established in 2010, Solvotrin Therapeutics is seeking EIIS funding to launch its groundbreaking iron supplement in early 2016.

Its chief executive Pat O’Flynn, a former Ernst & Young Entrepreneur of the Year finalist, said: “Solvotrin Therapeutics’ primary focus is on improving established therapies, making them better and safer with the added advantage of patent protection linked to a defined market need. We are very excited about the high impact of our women’s health portfolio, and the strength...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Buy now, sell always

Cyber tactics: workforce awareness is your critical first line of defence

Left to their own devices: reducing the digital divide

Skills for the new world